share_log

迪哲医药(688192.SH):高瑞哲(戈利昔替尼胶囊)获得国家药监局批准上市

Dizhe Pharmaceutical (688192.SH): Gao Ruizhe (Golixetinib capsules) received approval from the National Medical Products Administration (NMPA) to enter the market.

Gelonghui Finance ·  Jun 19 04:41

On June 19th, Gelunhui reported that DiZhe Pharmaceutical (688192.SH) announced that its self-developed Class I new drug Gao Ruizhe (generic name: Gori Xi Ti Ni capsule) has officially been approved by the National Medical Products Administration (NMPA) and is applicable to adult patients with relapsed or refractory peripheral T-cell lymphoma (r/rPTCL) who have received at least first-line systemic treatment. Gao Ruizhe is the world's first and only new drug that acts on the JAK/STAT pathway to treat peripheral T-cell lymphoma. Monotherapy has shown breakthrough advantages in terms of deep symptom relief, comprehensive benefits in all subtypes, and markedly extended survival.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment